Open AccessThe Implications of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial: A Return to First Principles
Author(s) -
Musunuru Kiran,
Blumenthal Roger S.
Publication year - 2008
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20405
Subject(s) - ezetimibe , simvastatin , medicine , hyperlipidemia , context (archaeology) , familial hypercholesterolemia , cholesterol , cardiology , pharmacology , endocrinology , diabetes mellitus , paleontology , biology
To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low‐density lipoprotein (LDL) cholesterol (LDL‐C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid‐lowering agents? Copyright © 2008 Wiley Periodicals, Inc.